Ignite Creation Date:
2024-05-06 @ 7:47 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06132191
Status:
AVAILABLE
Last Update Posted:
2023-11-15
First Post:
2023-11-09
Brief Title:
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Sponsor:
Regeneron Pharmaceuticals
Organization:
Regeneron Pharmaceuticals
Study Overview
Official Title:
None
Status:
AVAILABLE
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Provide expanded access of cemiplimab in patients with solid tumors
Detailed Description:
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug IND applications Availability will depend on location
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None